Voya Financial Advisors, Inc. Genmab A/S Transaction History

Voya Financial Advisors, Inc.

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2021 Aug 16, 2021	SELL	$32.88 - $44.57 $336,756 - $456,485	-10,242 Closed	0 $0
Q1 2021 May 17, 2021	BUY	$30.92 - $44.4 $54,944 - $78,898	1,777 Added 20.99%	10,242 $325,000
Q4 2020 Mar 05, 2021	BUY	$33.66 - $40.76 $44,431 - $53,803	1,320 Added 18.47%	8,465 $345,000
Q3 2020 Nov 16, 2020	SELL	$33.07 - $38.68 $3,935 - $4,602	-119 Reduced 1.64%	7,145 $267,000
Q2 2020 Aug 14, 2020	BUY	$20.05 - $33.89 $145,643 - $246,176	7,264 New	7,264 $237,000

237

48.6M

6.8K

27.6K

Ticker GMAB
Exchange OTC
Sector Healthcare
Industry Biotechnology
Shares Outstandng 658,292,992
Market Cap $14.8B
Description
Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; ofatumurnab, a human monoclonal antibody to treat chronic lymphoc...

Get notified when there are updates to the investment portfolio of Voya Financial Advisors, Inc., based on Form 13F filings with the SEC.

Stay updated on Voya Financial Advisors, Inc. with notifications on news.